Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Ubamatamab (Synonyms: REGN4018)

Catalog No. T76967 Copy Product Info
🥰Excellent
Ubamatamab represents a highly specialized bispecific T-cell engaging antibody specifically engineered to bridge the structural gap between MUC16-expressing malignant ovarian cancer cells and cytotoxic T-lymphocytes by maintaining stable engagement with the CD3 receptor complex to evaluate the induction of tumor-specific immune responses across various preclinical experimental models in specialized oncology research environments.

Ubamatamab

Copy Product Info
🥰Excellent
Catalog No. T76967
Synonyms REGN4018

Ubamatamab represents a highly specialized bispecific T-cell engaging antibody specifically engineered to bridge the structural gap between MUC16-expressing malignant ovarian cancer cells and cytotoxic T-lymphocytes by maintaining stable engagement with the CD3 receptor complex to evaluate the induction of tumor-specific immune responses across various preclinical experimental models in specialized oncology research environments.

Ubamatamab
Cas No. 2305629-50-7
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$479-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:>95% (SDS-PAGE); 98.42% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Ubamatamab represents a highly specialized bispecific T-cell engaging antibody specifically engineered to bridge the structural gap between MUC16-expressing malignant ovarian cancer cells and cytotoxic T-lymphocytes by maintaining stable engagement with the CD3 receptor complex to evaluate the induction of tumor-specific immune responses across various preclinical experimental models in specialized oncology research environments.
In vitro
In T-cell engagement assays using ovarian cancer cell lines, Ubamatamab (REGN4018) facilitated cytolytic synapse formation with MUC16-expressing tumor cells, leading to target cell lysis [1].
In vivo
In MUC16-expressing human tumor xenograft models, systemic administration of Ubamatamab (REGN4018) resulted in significant tumor regression and durable antitumor immunity [1].
SynonymsREGN4018
Reactivity
Human
Verified Activity
OVCAR-3 cells at 1×10^5 cells/well can bind Ubamatamab. The EC50 is 0.421 nM.
huCD3e-Jurkat cells at 1×10^5 cells/well can bind Ubamatamab. The EC50 is 15.06 nM.
verifiedActivityverifiedActivity
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetCD3E & MUC16
Chemical Properties
Molecular Weight144.64 kDa
Cas No.2305629-50-7
Antibody Information
IsotypeHuman IgG4 kappa
Recommended Isotype Control
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Ubamatamab | purchase Ubamatamab | Ubamatamab cost | order Ubamatamab | Ubamatamab in vivo | Ubamatamab in vitro | Ubamatamab molecular weight